B+
Bull case
25%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
QTTB
Q32 BioFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The core bull case is that Q32 has narrowed the story to bempikibart, completed SIGNAL-AA Part B enrollment, and still guides to a mid-2026 topline readout while runway extends into late 2027 if management assumptions hold [#10-K-2026-03-10] [#PR-2026-03-10].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.9.
What can break
ATM usage could create incremental dilution and pressure sentiment.
Momentum
8
Value
57
Sentiment
19
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.50 · Bull $10.00 · Bear $2.50Analysis 2026-04-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $39.43
Why
Momentum8 · Δ7d +1.2
Value57 · Δ7d -0.9
Sentiment19 · Δ7d -10.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.9.
Contradictions & invalidation
- • ATM usage could create incremental dilution and pressure sentiment.
- • Mid-2026 SIGNAL-AA Part B results may disappoint or slip.
- • The bear case is that this remains a one-asset, low-coverage biotech with a negative deterministic prior, modest evidence quality, and explicit dependence on future capital beyond current runway; any readout delay, weaker efficacy, or use of the ATM could pressure shares materially [#8-K-2026-03-27] [#10-K-2026-03-10].
Catalyst clock
2026-07-15
SIGNAL-AA Part B 36-week topline data in mid-2026
Lead driver: Value · See fundamentals
Momentum
8
8% active weight
Current posture
7d trendSoftening
Δ7d
+1.2
Δ21d
+3.5
Value
57
47% active weight
Current posture
7d trendFlat
Δ7d
-0.9
Δ21d
-1.1
Sentiment
19
45% active weight
Current posture
7d trendSoftening
Δ7d
-10.3
Δ21d
-6.8
Why this grade
Composite grade F. Momentum 8.2 / Value 57.5 / Sentiment 19.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$257.51M
Beta
0.17
Shares Out
29.77M
P/E (TTM) · Derived
3.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-6.02
Rev YoY
-100.0%
EPS YoY
-43.5%
Gross Margin
+99.3%
Op Margin
-
Net Debt
-$32.95M
Current Ratio
20.28
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data